Curated News
By: NewsRamp Editorial Staff
May 21, 2025
Tonix Pharmaceuticals Initiates Phase 2 OASIS Trial for Acute Stress Reaction
TLDR
- First patient dosed in Phase 2 OASIS trial by Tonix Pharmaceuticals offers potential market advantage for TNX-102 SL.
- Tonix Pharmaceuticals is conducting Phase 2 OASIS trial for TNX-102 SL to evaluate reducing acute stress reaction severity and onset of acute stress disorder.
- Tonix Pharmaceuticals' Phase 2 OASIS trial aims to provide urgent treatments to civilian and military populations following traumatic events for a better tomorrow.
- TNX-102 SL by Tonix Pharmaceuticals, with improvements in sleep and early PTSD symptoms, shows promise in mitigating acute stress reaction severity.
Impact - Why it Matters
This news matters as it addresses the critical need for therapies to mitigate acute stress reaction in trauma survivors. The Phase 2 trial's potential success could lead to advancements in treating acute stress disorder, impacting both civilian and military populations.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) has dosed the first patient in the Phase 2 OASIS trial to evaluate TNX-102 SL for reducing acute stress reaction severity and the onset of acute stress disorder. The trial, sponsored by the University of North Carolina's Institute for Trauma Recovery, will enroll about 180 motor vehicle trauma survivors. CEO Dr. Seth Lederman highlighted the urgent need for treatments following traumatic events in both civilian and military populations.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Tonix Pharmaceuticals Initiates Phase 2 OASIS Trial for Acute Stress Reaction
